Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Yu-Li Hospital |
---|---|
Information provided by: | Yu-Li Hospital |
ClinicalTrials.gov Identifier: | NCT00468533 |
A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome |
Drug: Aripiprazole |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial |
Estimated Enrollment: | 50 |
Study Start Date: | May 2006 |
Estimated Study Completion Date: | July 2007 |
Ages Eligible for Study: | 16 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients may be included in the study if they meet the following criteria:
Exclusion Criteria:
Patients may be excluded from the study for any of the following reasons:
Contact: Tsuo-Hung Lan, MD, PhD | 886-3-8886141 ext 2221 | tosafish@gmail.com |
Taiwan | |
Yu-Li Hospital, DOH | Recruiting |
Hualien, Taiwan, 981 | |
Contact: Hsien-Jane Chiu, MD, MPH, PhD 03-8886141 ext 2220 ylh.ebmc@gmail.com | |
Principal Investigator: Tsuo-Hung Lan, MD, PhD |
Principal Investigator: | Tsuo-Hung Lan, MD, PhD | Yu-Li Hospital |
Study ID Numbers: | YLH-IRB-9506 |
Study First Received: | April 30, 2007 |
Last Updated: | April 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00468533 History of Changes |
Health Authority: | Taiwan: Department of Health |
Arupiprazole, prolacin, PANSS, CGI, AIMS |
Tranquilizing Agents Psychotropic Drugs Central Nervous System Depressants Central Nervous System Diseases Antipsychotic Agents Dyskinesias Tardive Dyskinesia Schizophrenia |
Signs and Symptoms Movement Disorders Mental Disorders Neurologic Manifestations Psychotic Disorders Aripiprazole Oral Facial Dyskinesia Schizophrenia and Disorders with Psychotic Features |
Tranquilizing Agents Disease Physiological Effects of Drugs Nervous System Diseases Psychotropic Drugs Central Nervous System Depressants Central Nervous System Diseases Antipsychotic Agents Dyskinesias Pharmacologic Actions Schizophrenia |
Signs and Symptoms Pathologic Processes Movement Disorders Mental Disorders Therapeutic Uses Syndrome Neurologic Manifestations Aripiprazole Central Nervous System Agents Schizophrenia and Disorders with Psychotic Features |